Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupportContact
Search
Close

UK MHRA publishes “top tips” for manufacturing authorisation applicants

By Jane Summerfield & Julia Fraser on January 6, 2017
Email this postTweet this postLike this postShare this post on LinkedIn

The UK Medicines and Healthcare products Regulatory Agency (“MHRA”) has published guidance for companies submitting a Manufacturing Authorisation application or variation on common mistakes made by applicants, to help reduce delays in processing applications.

The MHRA is required to grant or refuse applications for manufacturing authorisations within 90 days of receiving a completed application. The MHRA receives over 800 manufacturing authorisation related applications each year and over 30% of these require further information before the MHRA can begin processing the application, causing delays.

The MHRA has identified 6 common mistakes made in applications and has provided guidance to help companies address these:

  1. Ensure that application forms are complete and attach all the supporting documentations.
  2. Only include activities that the company is capable of performing at the time of the application (and not those that it might perform in future).
  3. Ensure that the nominated key personnel have experience at the relevant site and knowledge of the site’s Pharmaceutical Quality System.
  4. Only name contract laboratories in the application if they are performing an inspectable activity such as testing of finished products prior to batch release or stability testing of finished products.
  5. Storage only sites for stability samples that do not conduct any testing and are not being stored for wholesale dealing purposes do not need be included in the application.
  6. Sites should be ready for inspection. The QP/QA team must have carried out a full scope self-inspection to confirm the site’s readiness for inspection and have an action plan in place to address any deficiencies identified.

The last point is particularly important as Inspectors must issue a GMP Certificate or a Statement of Non-Compliance (“SoNC”) within 90 days of the inspection. If the site is not ready or the Inspector is not satisfied with any corrective and preventative actions proposed by the QP/QA team, the Inspector may recommend that the application be refused or a SoNC issued. The applicant will incur additional costs as well as delays if a follow-up inspection is required or a new application has to be submitted.

The full guidance is available here.

Photo of Jane Summerfield Jane Summerfield

Partner, London

Jane focuses on regulatory compliance and commercial agreements in the life sciences and food sectors. Jane advises on legal and regulatory requirements that apply during the product lifecycle, including clinical trial requirements, early access schemes, marketing authorisations, manufacturing and distribution licences…

Partner, London

Jane focuses on regulatory compliance and commercial agreements in the life sciences and food sectors. Jane advises on legal and regulatory requirements that apply during the product lifecycle, including clinical trial requirements, early access schemes, marketing authorisations, manufacturing and distribution licences, CE marking, product labelling, product composition, advertising and marketing activities, and pricing and reimbursement. Jane also advises on a wide range of commercial contractual arrangements, including consultancy, sponsorship, co-promotion, collaboration, manufacturing, distribution, services, quality and pharmacovigilance agreements, as well as helping clients to resolve issues with UK enforcement authorities and regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA), Prescription Medicines Code of Practice Authority (PMCPA), Advertising Standards Authority (ASA), Food Standards Agency (FSA) and Trading Standards.
Jane combines commercial acumen with deep regulatory knowledge. She understands the business pressures faced by clients, having provided in-house regulatory compliance and commercial support to a major pharmaceutical client and a multinational food company. Jane provides “clear responses with business impact” Chambers UK.

Read more about Jane SummerfieldEmail
Show more Show less
  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Focus on Regulation
  • Organization:
    Hogan Lovells
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
The Library at LexBlog
  • About LexBlog
  • The Field We Built
  • Library at LexBlog
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo